Defining early-onset kidney cancer: Implications for germline and somatic mutation testing and clinical management - Abstract

PURPOSE: Approximately 5% to 8% of renal cell carcinoma (RCC) is hereditary.

No guidelines exist for patient selection for RCC germline mutation testing. We evaluate how age of onset could indicate the need for germline mutation testing for detection of inherited forms of kidney cancer.

PATIENTS AND METHODS: We analyzed the age distribution of RCC cases in the SEER-17 program and in our institutional hereditary kidney cancer population. The age distributions were compared by sex, race, histology, and hereditary cancer syndrome. Models were established to evaluate the specific age thresholds for genetic testing.

RESULTS: The median age of patients with RCC in SEER-17 was 64 years, with the distribution closely approaching normalcy. Statistical differences were observed by race, sex, and subtype (P < .05). The bottom decile cutoff was ≤ 46 years of age and slightly differed by sex, race, and histology. The mean and median ages at presentation of 608 patients with hereditary kidney cancer were 39.3 years and 37 years, respectively. Although age varied by specific syndrome, 70% of these cases were found to lie at or below the bottom age decile. Modeling age-based genetic testing thresholds demonstrated that the 10th percentile maximized sensitivity and specificity.

CONCLUSION: Early age of onset might be a sign of hereditary RCC. Even in the absence of clinical manifestations and personal/family history, an age of onset of 46 years or younger should trigger consideration for genetic counseling/germline mutation testing and may serve as a useful cutoff when establishing genetic testing guidelines.

Written by:
Shuch B, Vourganti S, Ricketts CJ, Middleton L, Peterson J, Merino MJ, Metwalli AR, Srinivasan R, Linehan WM.   Are you the author?
Center for Cancer Research, National Cancer Institute, Bethesda, MD.

Reference: J Clin Oncol. 2014 Feb 10;32(5):431-7.
doi: 10.1200/JCO.2013.50.8192


PubMed Abstract
PMID: 24378414

UroToday.com Renal Cancer Section